ClinicalTrials.gg
CompletedNCT05048342BISCUITUpdated Apr 8, 2025Results posted

A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines

A Phase 3 interventional study of LOU064 in Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in Japan. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing remibrutinib in Chronic Urticaria — 2 open to participants now, 6 under way, 5 of them phase 3. remibrutinib · Chronic Urticaria.

Enrollment
11th of 12
71 · median 347
Started
2022
with 1 other
Phase 3
9 of 12
1 open now
Registered
5th of 12
by date
Lead sponsor
12 of 12
Novartis Pharmaceuticals

Among the 12 studies testing remibrutinib in Chronic Urticaria, this one is the 11th largest by enrollment, is one of 2 that started in 2022, is one of 9 in phase 3, and was the 5th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 48 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

2 of the 12 studies testing remibrutinib in Chronic Urticaria are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About remibrutinib

remibrutinib: first FDA approval 2025 (RHAPSIDO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing remibrutinib in Chronic Urticaria, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the safety, tolerability and efficacy of remibrutinib (LOU064) in adult Japanese patients chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment by H1-antihistamine (H1-AH) at locally label approved doses, for a duration of 52 weeks of treatment with remibrutinib and a post-treatment follow-up period of up to 4 weeks.

Read the detailed description

The study consisted of three periods, the total study duration is up to 60 weeks: screening period of up to 4 weeks, open-label treatment period of 52 weeks (remibrutinib 25 mg b.i.d.), and a treatment free follow-up period of 4 weeks.

It was planned to include approximately 70 patients in the study; 71 patients were enrolled and included in the analyses.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • Bruton Tyrosine Kinase (BTK) inhibitor
  • Chronic Spontaneous Urticaria (CSU)
  • Urticaria Activity Score (UAS)
  • Weekly Urticaria Activity Score (UAS7)
  • Hives Severity Score (HSS)
  • Weekly Hives Severity Score (HSS7)
  • Itch Severity Score (ISS)
  • Weekly Itch Severity Score (ISS7)
  • Angioedema Activity Score (AAS)
  • Weekly Angioedema Activity Score (AAS7)
  • Dermatology Life Quality Index (DLQI)
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed was required to be obtained prior to participation in the study.
  • Male and female patients >= 18 years of age at the time of screening
  • CSU duration for >= 6 months prior to screening (defined as the onset of CSU determined by the Investigator based on all available supporting documentation)
  • Diagnosis of CSU inadequately controlled by second generation H1-AHs at the time of baseline (Day 1) defined as:

    • The presence of itch and hives for >= 6 consecutive weeks prior to screening despite the use of second generation H1-AHs during this time period
    • UAS7 score (range 0-42) >= 16, ISS7 score (range 0-21) >= 6 and HSS7 score (range 0-21) >= 6 during the 7 days prior to baseline (Day 1)
  • Documentation of hives within three months before baseline (either at screening and/or at baseline; or documented in the patients' medical history)
  • Willing and able to complete an UPDD for the duration of the study and adhere to the study protocol
  • Patients were required to not have more than one missing UPDD entry (either morning or evening) in the 7 days prior to baseline (Day 1)

Exclusion criteria

Exclusion criteria:

  • Patients having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria
  • Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary angioedema, or drug-induced urticaria
  • Any other skin disease associated with chronic itching that might influence in the Investigator's opinion the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis
  • Evidence of cardiovascular (such as but not limited to myocardial infarction, unstable ischemic heart disease, Class III/IV left ventricular failure, arrhythmia and uncontrolled hypertension within 12 months prior to Visit 1), neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the Investigator's opinion, would compromise the safety of the patient, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the patient
  • Significant bleeding risk or coagulation disorders
  • History of gastrointestinal bleeding, e.g., in association with use of nonsteroidal anti-inflammatory drugs, that was clinically relevant (e.g., for which intervention was indicated or requiring hospitalization or blood transfusion)
  • Requirement for anti- medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited.
  • Requirement for anticoagulant medication (for example, warfarin or Novel Oral Anti-Coagulants)
  • History or current hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or /ALT levels of more than 1.5 × or (INR) of more than 1.5 at screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    LOU064 25 mg b.i.d.

    Patients were treated with remibrutinib 25 mg bis in die/twice a day (b.i.d.). LOU064 open-label treatment taken orally for 52 weeks.

    Drug: LOU064

Interventions

  • DrugLOU064

    Each patient took one film-coated tablet in the morning and one film-coated tablet in the evening (except the morning dose at the PK sampling visits, which were to be taken on site during the visit).

    Also known as: remibrutinib

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events

    An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. Treatment emergent Adverse Event (TEAEs) in this study are events that started after the first dose of study treatment and until 30 days after the last study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 30 days after the last study treatment.

    Time frame: Baseline up to 30 days after last dose of study medication, assessed up to approximately 56 weeks

Secondary outcomes

  1. Mean Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12

    Change from Baseline in Weekly Urticaria Activity Score (UAS7) was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The Weekly Urticaria Activity Score (UAS7) is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the weekly UAS7 score is 0 - 42 (highest hives and itch severity).

    Time frame: Baseline, Week 12

  2. Number of Participants Who Achieved Disease Activity Control (UAS7 =< 6) at Week 12

    The percentage of patients achieving disease activity control (UAS7 =\< 6) at Week 12 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

    Time frame: Week 12

  3. Number of Participants Who Achieved Complete Absence of Hives and Itch (UAS7 = 0) at Week 12

    The proportion of patients achieving complete absence of hives and itch (UAS7 = 0) at Week 12 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

    Time frame: Week 12

  4. Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12

    The severity of the itch was recorded by the participant twice daily in their electronic Diary, on a scale of 0 (none) to 3 (severe). A weekly score (ISS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest itch severity).

    Time frame: Baseline, Week 12

  5. Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12

    The hives (wheals) severity score, defined by number of hives, was recorded by the participant twice daily in their electronic Diary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly score (HSS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest hives activity).

    Time frame: Baseline, Week 12

  6. Number of Participants Who Achieved Early Onset of Disease Activity Control (UAS7 =< 6) at Week 2

    The percentage of patients achieving disease activity control (UAS7 =\< 6) at Week 2 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

    Time frame: Week 2

  7. Number of Participants Who Achieved Dermatology Life Quality Index (DLQI) = 0-1 at Week 12

    The Dermatology Life Quality Index (DLQI) is a 10-item (grouped in 6 domains) dermatology-specific quality of life (QoL) measure. Participants are rating their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). Domain scores are calculated for: Symptoms and Feelings (0-6), Daily Activities (0-6), Leisure (0-6), Work and School (0-3), Personal Relationships (0-6), Treatment (0-3). The overall DLQI score range was split into score bands and validated in terms of their meaning/relevance to patients as follows: 0-1 (No effect on patient's life), 2-5 (Small effect on patient's life), 6-10 (Moderate effect on patient's life), 11-20 (Very large effect on patient's life), 21-30 (Extremely large effect on patient's life).

    Time frame: Week 12

  8. Mean Cumulative Number of Weeks With Disease Activity Control (UAS7 =< 6) up to Week 12

    Maintaining disease activity control was assessed as cumulative number of weeks with an UAS7 =\< 6 response between baseline and Week 12. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

    Time frame: Up to Week 12

  9. Mean Cumulative Number of Angioedema Occurrence-free Weeks (AAS7 = 0 Response) up to Week 12

    Angioedema occurrence was recorded once daily in the evening in the electronic Diary by the participant. Reporting the occurrence of angioedema was used as opening question for the assessment of the Angioedema Activity Score (AAS). The AAS consists of 5 questions with 4 answer options (scored 0-3) for each item, with a minimum score of 0 and a maximum score of 15 per day. The AAS score over 7 days (AAS7) ranges from 0 (no angioedema episodes) to 105 (highest angioedema severity).

    Time frame: Up to Week 12

07

Results

Posted Nov 22, 2024

Participant flow

This study was conducted at 13 centers in Japan.

Participant flow — Overall Study
MilestoneLOU064 25 mg b.i.d.
Started71
Completed68
Not completed3
Withdrew: Adverse event1
Withdrew: Subject decision2

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events

An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. Treatment emergent Adverse Event (TEAEs) in this study are events that started after the first dose of study treatment and until 30 days after the last study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 30 days after the last study treatment.

Time frame:
Baseline up to 30 days after last dose of study medication, assessed up to approximately 56 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsLOU064 25 mg b.i.d.
Subjects with at least one Adverse Event (AE)62
Subjects with serious or other significant events - Death0
Subjects with serious or other significant events - Non-fatal SAE(s)3
Subjects with serious or other significant events - Discontinued study treatment due to any AE(s)1
SecondaryMean Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12

Change from Baseline in Weekly Urticaria Activity Score (UAS7) was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The Weekly Urticaria Activity Score (UAS7) is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the weekly UAS7 score is 0 - 42 (highest hives and itch severity).

Time frame:
Baseline, Week 12
Reported as:
Mean · Unit on a scale
Mean Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12
Unit on a scaleLOU064 25 mg b.i.d.
Mean Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12-18.14 ± 10.992
SecondaryNumber of Participants Who Achieved Disease Activity Control (UAS7 =< 6) at Week 12

The percentage of patients achieving disease activity control (UAS7 =\< 6) at Week 12 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Disease Activity Control (UAS7 =< 6) at Week 12
ParticipantsLOU064 25 mg b.i.d.
Number of Participants Who Achieved Disease Activity Control (UAS7 =< 6) at Week 1230
SecondaryNumber of Participants Who Achieved Complete Absence of Hives and Itch (UAS7 = 0) at Week 12

The proportion of patients achieving complete absence of hives and itch (UAS7 = 0) at Week 12 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Complete Absence of Hives and Itch (UAS7 = 0) at Week 12
ParticipantsLOU064 25 mg b.i.d.
Number of Participants Who Achieved Complete Absence of Hives and Itch (UAS7 = 0) at Week 1215
SecondaryChange From Baseline in Weekly Itch Severity Score (ISS7) at Week 12

The severity of the itch was recorded by the participant twice daily in their electronic Diary, on a scale of 0 (none) to 3 (severe). A weekly score (ISS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest itch severity).

Time frame:
Baseline, Week 12
Reported as:
Mean · Unit on a scale
Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12
Unit on a scaleLOU064 25 mg b.i.d.
Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12-8.01 ± 4.703
SecondaryChange From Baseline in Weekly Hives Severity Score (HSS7) at Week 12

The hives (wheals) severity score, defined by number of hives, was recorded by the participant twice daily in their electronic Diary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly score (HSS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest hives activity).

Time frame:
Baseline, Week 12
Reported as:
Mean · Unit on a scale
Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12
Unit on a scaleLOU064 25 mg b.i.d.
Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12-10.12 ± 6.845
SecondaryNumber of Participants Who Achieved Early Onset of Disease Activity Control (UAS7 =< 6) at Week 2

The percentage of patients achieving disease activity control (UAS7 =\< 6) at Week 2 was assessed to evaluate the efficacy of Remibrutinib in Chronic Spontaneous Urticaria (CSU) patients. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

Time frame:
Week 2
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Early Onset of Disease Activity Control (UAS7 =< 6) at Week 2
ParticipantsLOU064 25 mg b.i.d.
Number of Participants Who Achieved Early Onset of Disease Activity Control (UAS7 =< 6) at Week 229
SecondaryNumber of Participants Who Achieved Dermatology Life Quality Index (DLQI) = 0-1 at Week 12

The Dermatology Life Quality Index (DLQI) is a 10-item (grouped in 6 domains) dermatology-specific quality of life (QoL) measure. Participants are rating their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). Domain scores are calculated for: Symptoms and Feelings (0-6), Daily Activities (0-6), Leisure (0-6), Work and School (0-3), Personal Relationships (0-6), Treatment (0-3). The overall DLQI score range was split into score bands and validated in terms of their meaning/relevance to patients as follows: 0-1 (No effect on patient's life), 2-5 (Small effect on patient's life), 6-10 (Moderate effect on patient's life), 11-20 (Very large effect on patient's life), 21-30 (Extremely large effect on patient's life).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Dermatology Life Quality Index (DLQI) = 0-1 at Week 12
ParticipantsLOU064 25 mg b.i.d.
Number of Participants Who Achieved Dermatology Life Quality Index (DLQI) = 0-1 at Week 1239
SecondaryMean Cumulative Number of Weeks With Disease Activity Control (UAS7 =< 6) up to Week 12

Maintaining disease activity control was assessed as cumulative number of weeks with an UAS7 =\< 6 response between baseline and Week 12. The UAS7 is the sum of the Weekly Hives Severity Score (HSS7) and the Weekly Itch Severity Score (ISS7). The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

Time frame:
Up to Week 12
Reported as:
Mean · Weeks
Mean Cumulative Number of Weeks With Disease Activity Control (UAS7 =< 6) up to Week 12
WeeksLOU064 25 mg b.i.d.
Mean Cumulative Number of Weeks With Disease Activity Control (UAS7 =< 6) up to Week 124.6 ± 4.86
SecondaryMean Cumulative Number of Angioedema Occurrence-free Weeks (AAS7 = 0 Response) up to Week 12

Angioedema occurrence was recorded once daily in the evening in the electronic Diary by the participant. Reporting the occurrence of angioedema was used as opening question for the assessment of the Angioedema Activity Score (AAS). The AAS consists of 5 questions with 4 answer options (scored 0-3) for each item, with a minimum score of 0 and a maximum score of 15 per day. The AAS score over 7 days (AAS7) ranges from 0 (no angioedema episodes) to 105 (highest angioedema severity).

Time frame:
Up to Week 12
Reported as:
Mean · Weeks
Mean Cumulative Number of Angioedema Occurrence-free Weeks (AAS7 = 0 Response) up to Week 12
WeeksLOU064 25 mg b.i.d.
Mean Cumulative Number of Angioedema Occurrence-free Weeks (AAS7 = 0 Response) up to Week 1210.0 ± 3.63

Adverse events

Collected over On-treatment adverse events and deaths were reported from first dose of study medication up to 30 days after last dose of study medication, assessed up to approximately 56 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LOU064 25 mg b.i.d.0/71 (0%)3/71 (4.2%)53/71 (74.6%)
Most frequent serious events
Most frequent serious events
EventLOU064 25 mg b.i.d.
Meniere's diseaseEar and labyrinth disorders1/71
Epiretinal membraneEye disorders1/71
Rhegmatogenous retinal detachmentEye disorders1/71
Most frequent other events
Showing 10 of 14
Most frequent other events
EventLOU064 25 mg b.i.d.
COVID-19Infections and infestations14/71
HeadacheNervous system disorders9/71
NasopharyngitisInfections and infestations7/71
Dermatitis atopicSkin and subcutaneous tissue disorders7/71
DiarrhoeaGastrointestinal disorders6/71
EczemaSkin and subcutaneous tissue disorders6/71
TonsillitisInfections and infestations5/71
AcneSkin and subcutaneous tissue disorders5/71
PyrexiaGeneral disorders4/71
CystitisInfections and infestations4/71

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LOU064 25 mg b.i.d.
Mean43.5 ± 12.52
Age, Customized
Age, Customized(Participants)LOU064 25 mg b.i.d.
>= 18 and < 65 years66
>= 65 and < 85 years5
Sex: Female, Male
Sex: Female, Male(Participants)LOU064 25 mg b.i.d.
Female54
Male17
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LOU064 25 mg b.i.d.
Asian71
08

Study locations

13 sites
  • Novartis Investigative Site
    Nagoya, Aichi 454-0012, Japan
  • Novartis Investigative Site
    Urayasu, Chiba 279-0011, Japan
  • Novartis Investigative Site
    Izumiotsu, Osaka 595-0025, Japan
  • Novartis Investigative Site
    Neyagawa, Osaka 572-0838, Japan
  • Novartis Investigative Site
    Sakai, Osaka 593-8324, Japan
  • Novartis Investigative Site
    Takatsuki, Osaka 569-0824, Japan
  • Novartis Investigative Site
    Izumo-city, Shimane 693 8501, Japan
  • Novartis Investigative Site
    Itabashi-ku, Tokyo 173-8610, Japan
  • Novartis Investigative Site
    Minato, Tokyo 108-0014, Japan
  • Novartis Investigative Site
    Ota-ku, Tokyo 143-0023, Japan
  • Novartis Investigative Site
    Fukuoka, 811-1302, Japan
  • Novartis Investigative Site
    Osaka, 554 0014, Japan
  • Novartis Investigative Site
    Osaka, 558-0003, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Dec 2023, 22 months.

Results were first posted in Nov 2024, 11 months after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 22 months is close to that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2021
First posted
Sep 17, 2021
StartActual
Jan 15, 2022
Primary completionActual
Dec 8, 2023
CompletionActual
Dec 9, 2023
Results first posted
Nov 22, 2024
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05048342
Responsible party
Sponsor
First posted
Sep 17, 2021
Start date
Jan 15, 2022
Primary completion
Dec 8, 2023
Completion
Dec 9, 2023
Results posted
Nov 22, 2024
Last update
Apr 8, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion